Related references
Note: Only part of the references are listed.SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease
Kristin M. D'Silva et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
Anja Strangfeld et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Timing of rituximab and immunoglobulin level influence the risk of death for COVID-19 in ANCA-associated vasculitis
Luca Quartuccio et al.
RHEUMATOLOGY (2021)
COMPARISON OF EQ-5D HEALTH STATUS IN PSORIATIC ARTHRITIS PATIENTS WITH OR WITHOUT AXIAL DISEASE: RESULTS OF SUBANALYSIS OF THE PATERA STUDY
I. Gaydukova et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?
Roch Houot et al.
EUROPEAN JOURNAL OF CANCER (2020)
346. Factors influencing B cell repopulation after remission induction with rituximab in newly diagnosed, treatment–naïve patients with ANCA-associated vasculitis
Chiara Salviani et al.
RHEUMATOLOGY (2019)
Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients
J. Westra et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2014)
Impact of rituximab trials on the treatment of ANCA-associated vasculitis
Federico Alberici et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2014)
Share Paper
